Compare CNVS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNVS | RNTX |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 38.9M |
| IPO Year | 2003 | N/A |
| Metric | CNVS | RNTX |
|---|---|---|
| Price | $2.32 | $1.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $10.00 |
| AVG Volume (30 Days) | 146.2K | ★ 234.4K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $79,791,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $36.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 77.29 | N/A |
| 52 Week Low | $2.24 | $1.04 |
| 52 Week High | $7.39 | $3.50 |
| Indicator | CNVS | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.74 | 53.37 |
| Support Level | $2.40 | $1.34 |
| Resistance Level | $2.51 | $1.58 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 34.15 | 62.50 |
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.